Challenges for HER2neg EBC

CE / CME

Current Challenges With Individualizing Therapy for HER2-Negative Early-Stage Breast Cancer

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Pharmacists: 0.25 contact hour (0.025 CEUs)

Released: April 03, 2024

Expiration: April 02, 2025

Tanya Gupta
Tanya Gupta, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

You and your colleagues are discussing the next steps for a patient with high-risk, node-positive HR-positive/HER2-negative EBC who is negative for germline BRCA1/2 mutations. She has been experiencing problematic diarrhea since initiating adjuvant abemaciclib plus endocrine therapy, despite the care team maximizing supportive measures and dose reducing abemaciclib to the lowest dose level.

Which of the following would you recommend for this patient?